Pulmonary Hypertension Clinical Trial
Official title:
Inhaled Versus Intravenous Milrinone for Patients Undergoing Mitral Valve Replacement Surgery
This prospective double blinded randomized study aims to compare the effect of inhaled versus intravenous milrinone on the pulmonary vascular resistance in patients undergoing mitral valve replacement surgery. The primary outcome is to determine change in pulmonary artery pressure. The secondary outcomes include, - Incidence of systemic hypotension. - Hemodynamic affection and need of vasopressors and inotropes. - Change in pulmonary vascular resistance versus systemic vascular resistance. - Right ventricular function. - Duration of mechanical ventilation. - Need for mechanical circulatory support devices. - Urine output - Length of intensive care (ICU) in stay. As the investigators hypothesize that inhaled milrinone has a selective pulmonary vasodilator effect devoid of the systemic hypotension with the intravenous administration.
Standard preoperative assessment for cardiac surgery will be done for all patients. Premedication will be given according to standard protocol in our university hospitals as follow bromazepam 3mg oral and ranitidine 150 mg orally in the night-before then another dose of ranitidine 150 mg 2 hours before arrival in operating theatre by small sips of clear liquid. On arrival to induction room wide bore IV access will be inserted using local anesthetic then arterial cannula in radial artery will be inserted the same manner using local anesthetic then in operating room routine monitoring including a five-lead electrocardiogram, pulse oximeter and invasive blood pressure will be attached. Anesthesia will be induced with midazolam 0.02 mg/kg and fentanyl 2-5 mcg/kg and muscle relaxation will be achieved by cis-atracurium 0.15 mg/kg. After tracheal intubation, central venous line and transesophageal echocardiography will be inserted, then anesthesia will be maintained throughout the procedure with morphine 20 mcg/kg/min, cis-atracurium 2 mcg/kg/min and sevoflurane 0.4% - 2% MAC. Ventilation will be adjusted to maintain end-tidal carbon dioxide in the range of 30-40 mmHg. During cardiopulmonary bypass, flow of 2.2 l/min/m2 will be achieved, 20 ml/kg cold blood cardioplegia will be given manually and pressure controlled at 20 - 30 min interval along with hot shot at start of weaning from CPB, temperature will be maintained at 32-34℃ and propofol 1% infusion at rate of 8 - 12ml/hr. In initial TEE study, baseline measures will be taken assessing left ventricular ejection fraction, and right ventricular hemodynamics represented by right ventricular function measured by [tricuspid annulus plane systolic excursion, fractional area changes, and right ventricular systolic pressure by doppler] also, pulmonary vascular resistance and systemic vascular resistance will be calculated, plus patients hemodynamics (mean arterial blood pressure, heart rate) and inotropic score all measures will be recorded. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01950585 -
Hydroxyurea in Pulmonary Arterial Hypertension
|
Early Phase 1 | |
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Completed |
NCT03649932 -
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
|
Phase 1 | |
Recruiting |
NCT04554160 -
Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
|
||
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT01894035 -
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
|
||
Not yet recruiting |
NCT04083729 -
Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy
|
N/A | |
Completed |
NCT02216279 -
Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension
|
Phase 2 | |
Terminated |
NCT02246348 -
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
|
N/A | |
Completed |
NCT02821156 -
Study on the Use of Inhaled NO (iNO)
|
N/A | |
Terminated |
NCT02243111 -
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
|
N/A | |
Recruiting |
NCT01913847 -
Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT06240871 -
Contrast Enhanced PA Pressure Measurements
|
||
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT02377934 -
Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
|
||
Recruiting |
NCT01091012 -
Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT02275793 -
The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
|
||
Completed |
NCT00739375 -
The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension.
|
Phase 1 | |
Completed |
NCT01463514 -
Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension
|
N/A | |
Completed |
NCT01484899 -
Smoking: a Risk Factor for Pulmonary Arterial Hypertension?
|
N/A |